| P2093 | author name string | Lucely Cetina | |
| | Tania Crombet | |
| | Rafael Bojalil | |
| | Alfonso Dueñas-González | |
| | Jaime Coronel | |
| | Sandra Avila | |
| | Roberto Jiménez-Lima | |
| | Mayra Ramos | |
| | Blanca Bazán | |
| | Eduardo Charco | |
| | Horacio Astudillo | |
| | Sergio Zapata | |
| P2860 | cites work | Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy | Q26993238 |
| | Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. | Q30361969 |
| | Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study | Q30434661 |
| | Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer | Q33407093 |
| | Improved survival with bevacizumab in advanced cervical cancer | Q33566222 |
| | The emerging role of nimotuzumab in the treatment of non-small cell lung cancer | Q34343043 |
| | Conservative management of early stage cervical cancer: is there a role for less radical surgery? | Q34660575 |
| | Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study | Q35154219 |
| | Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study | Q35695168 |
| | Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status | Q36484536 |
| | A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study | Q37294922 |
| | Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity | Q37558534 |
| | Nimotuzumab for pediatric diffuse intrinsic pontine gliomas | Q37822466 |
| | Epidermal growth factor receptor as a biomarker for cervical cancer | Q37843137 |
| | Emerging drugs for cervical cancer. | Q38005222 |
| | Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis | Q38209068 |
| | Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). | Q38396745 |
| | Featured article: autophagic activation with nimotuzumab enhanced chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma | Q39015925 |
| | Outcomes and prognosis of patients with recurrent cervical cancer after radical hysterectomy. | Q39567415 |
| | Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile | Q39621039 |
| | Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group | Q40350784 |
| | Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck | Q40359415 |
| | Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR. | Q42474675 |
| | Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha | Q43231623 |
| | A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. | Q43279004 |
| | Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer | Q44656784 |
| | Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. | Q45928394 |
| | A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer | Q46916475 |
| | Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients | Q47672907 |
| | Don't jump to rash conclusions. | Q54614399 |
| | Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. | Q54682625 |
| | Prolonged use of nimotuzumab in children with central nervous system tumors: safety and feasibility. | Q55460948 |
| | Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. | Q55470352 |
| | Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody | Q74802802 |
| | Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma | Q81892768 |
| | Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients | Q83015114 |
| | Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix | Q83737796 |
| | (Laterally) extended endopelvic resection: surgical treatment of locally advanced and recurrent cancer of the uterine cervix and vagina based on ontogenetic anatomy | Q84731444 |
| P433 | issue | 5 | |
| P921 | main subject | cervix uterine cancer | Q160105 |
| | chemotherapy | Q974135 |
| P304 | page(s) | 684-689 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Cancer Biology and Therapy | Q2544651 |
| P1476 | title | A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer | |
| P478 | volume | 16 | |